Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (30)

2022

  1. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293

  2. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

  3. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  3. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  5. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

    Breast Cancer Research and Treatment, Vol. 187, Núm. 2, pp. 467-476

  6. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2020

  1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

    Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998

  2. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

  3. Phase Ia study of anti-NAPI2B antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non–small cell lung cancer and platinum-resistant ovarian cancer

    Clinical Cancer Research, Vol. 26, Núm. 2, pp. 364-372

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

    Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961

  3. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

    Oncologist, Vol. 24, Núm. 5, pp. 603-611

2018

  1. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii91-viii92

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

  2. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21930-21937

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

  2. Phase 2 Study of Trabectedin in Patients With Hormone Receptor–Positive, HER-2–Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene

    Clinical Breast Cancer, Vol. 16, Núm. 5, pp. 364-371